This study is about testing a new drug, ipatasertib, along with usual chemotherapy drugs paclitaxel and carboplatin for treating advanced ovarian cancer. Ovarian cancer is a serious illness that affects the ovaries, and this study aims to see if adding ipatasertib helps in stopping cancer from growing further. Paclitaxel and carboplatin are chemotherapy medicines that work by killing or stopping the growth of cancer cells.
The study is in its early phase (Phase I/IB) to check how safe the combination of these drugs is, what side effects they might cause, and the best dose to use. Participants will take ipatasertib by mouth and receive paclitaxel and carboplatin through an IV (intravenous line) every 21 days for up to 3 cycles, unless there are bad side effects or the cancer worsens.
- Study involves multiple visits and may last several months.
- Participants will receive the combination of three drugs.
- Potential risks include typical chemotherapy side effects and those specific to ipatasertib.
After the study, participants will have follow-up visits at 30 and 90 days to check their health.